Nuvo Research to release Phase 2 WF10 data in Q1
Nuvo Research (TSX:NRI) plans to release, in the first quarter of 2015, the results of a confirmatory Phase 2 study for a potential blockbuster allergic rhinitis drug, WF10, which could be a...
View ArticleNuvo cites placebo effect in WF10 trial
Nuvo Research (TSX:NRI) cited a placebo effect for its WF10 failing to achieve statistical significance in a Phase 2 trial in Germany for the treatment of refractory allergic rhinitis. Each of the...
View Article
More Pages to Explore .....